Millennium reports AngioDynamics (ANGO) ownership under 5 percent
Rhea-AI Filing Summary
AngioDynamics, Inc. received an updated large-shareholder disclosure showing that investment entities affiliated with Millennium reported modest, passive stakes in its common stock. Integrated Core Strategies (US) LLC reported beneficial ownership of 551,565 shares, representing 1.3% of AngioDynamics’ common stock. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 842,548 shares, or 2.0% of the outstanding common stock, as of the event date of 12/31/2025. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics.
Positive
- None.
Negative
- None.
FAQ
What does the latest AngioDynamics (ANGO) Schedule 13G/A disclose?
The filing reports that several Millennium-affiliated entities, including Integrated Core Strategies (US) LLC and Millennium Management LLC, hold relatively small, passive beneficial stakes in AngioDynamics common stock as of 12/31/2025.
How many AngioDynamics shares does Integrated Core Strategies (US) LLC report owning?
Integrated Core Strategies (US) LLC reports beneficial ownership of 551,565 AngioDynamics common shares, representing 1.3% of the outstanding common stock.
What percentage of AngioDynamics does Millennium Management LLC report owning?
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 842,548 shares of AngioDynamics common stock, equal to 2.0% of the class.
Is the Millennium stake in AngioDynamics intended to influence control of the company?
No. The reporting parties certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of AngioDynamics, and are not held in connection with any transaction having that purpose or effect.
Why is this AngioDynamics ownership report labeled as Amendment No. 1?
The Schedule 13G/A is marked Amendment No. 1, indicating it updates a prior ownership report for AngioDynamics, reflecting the current beneficial holdings as of 12/31/2025.
Who signed the AngioDynamics Schedule 13G/A on behalf of the reporting entities?
Gil Raviv, Global General Counsel, signed for the Millennium-affiliated entities, and Israel A. Englander signed in his individual capacity, each certifying the accuracy of the information.